NEW YORK, March 10, 2017 /PRNewswire/ -- Lawsuits filed on behalf of individuals who allegedly experienced permanent alopecia due to the Taxotere chemotherapy medication continue to move forward in the multidistrict litigation underway in the U.S. District Court, Eastern District of Louisiana. Court records indicate that two Pretrial Orders were issued on February 13, 2017, including an Order outlining a proposed Common Benefit Order previously submitted by the parties. A second Pretrial Order addresses the Court's intent to appoint a Special Master for management, oversight, and substantive review of matters related to and claimed to be common benefit, as well as any other matters or recommendation as directed by the Court. (In Re: Taxotere (Docetaxal) Products Liability Litigation - MDL No. 2740)
"Our Firm is representing Taxotere clients in claims involving permanent hair loss, and we continue to receive inquiries from others seeking to file similar lawsuits. We are pleased with the progress of the federal litigation thus far, and the matters addressed in the Court's latest Pretrial Orders will help ensure that the proceeding continues to move forward efficiently," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is now offering free case reviews to breast cancer patients and others who experienced permanent hair loss allegedly associated with Taxotere cancer treatment.
Taxotere and Hair Loss
More than 800 Taxotere lawsuits have been filed in the Eastern District of Louisiana on behalf of individuals who allegedly experienced permanent hair loss following treatment with the chemotherapy agent. While Taxotere was first approved to treat breast cancer in 1996, it wasn't until December 2015 that mention of permanent alopecia was included on the drug's U.S. label. It is true that alopecia is a common side effect of chemotherapy. However, plaintiffs claim that Taxotere is more likely to result in the permanent loss of hair compared to alternative, equally effective drugs. They also claim that Sanofi-Aventis has long provided information regarding the potential for permanent alopecia to individual patients and regulatory agencies overseas. Yet Taxotere's U.S. label only included a generic, vague, and insufficient warning that "hair generally grows back".
Victims of permanent hair loss allegedly associated with Taxotere may be entitled to compensation for their emotional distress and other damages. To learn more about filing a Taxotere lawsuit, please visit Bernstein Liebhard LLP's website, or call 800-511-5092 to arrange for a free, no obligation case review.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/latest-taxotere-lawsuit-orders-address-common-benefit-order-and-appointment-of-special-master-bernstein-liebhard-llp-reports-300421945.html
SOURCE Bernstein Liebhard LLP